Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis
Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis
At Takeda Oncology, the Global Oncology Business Unit of Takeda Pharmaceutical Company Limited, we endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. We know that our mission is not a quick or simple one, but we are up to the task: we aspire to cure cancer.
At Takeda Oncology, we are changing what being a ‘patient driven’ organization really means. We know that by doing right for patients, we do right for the world and for the future of drug development.
Changing expectations in science means taking the path less traveled. Our research and development (R&D) efforts are focused on compounds that are either unprecedented in their approach or offer best-in-class advantages.
Every day we endeavour to improve the lives of people living with cancer and their loved ones by bringing innovative medicines to market as quickly, effectively and safely as possible. Our therapies span treatments for multiple types of cancer, particularly those that have not traditionally been the focus of oncology R&D.
We’re looking for partners who believe our global reach, deep scientific expertise and clinical excellence can help them bring their vision to market. We’ve been putting patients first for hundreds of years. Our centuries-old values of integrity, fairness, honesty and perseverance guide how we operate and how we work with partners. If better health and a brighter future for people everywhere is our why, partnering is our how. We believe deeply in the power of Takeda plus our partners.
At Takeda, every member of our team is working towards better health and a brighter future for people worldwide. If you want to make a difference and help us achieve our mission, contact us to find out more.
Join us for an #ICML19 poster presentation, in partnership with @SeattleGenetics, highlighting treatment responses by CD30 expression in the ECHELON-2 study. https://t.co/HlDtRgGoGk
@TakedaOncology • 6/19/2019
